Center For Asset Management LLC Acquires 1,243 Shares of Pfizer Inc. (NYSE:PFE)

Center For Asset Management LLC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 35,052 shares of the biopharmaceutical company’s stock after buying an additional 1,243 shares during the quarter. Center For Asset Management LLC’s holdings in Pfizer were worth $930,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the business. KBC Group NV increased its stake in shares of Pfizer by 6.3% in the 4th quarter. KBC Group NV now owns 3,301,369 shares of the biopharmaceutical company’s stock worth $87,586,000 after purchasing an additional 195,936 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new stake in Pfizer in the fourth quarter worth about $4,322,000. Apexium Financial LP raised its stake in shares of Pfizer by 72.5% in the fourth quarter. Apexium Financial LP now owns 22,772 shares of the biopharmaceutical company’s stock worth $604,000 after buying an additional 9,570 shares during the period. Capital Asset Advisory Services LLC lifted its position in shares of Pfizer by 6.4% during the 4th quarter. Capital Asset Advisory Services LLC now owns 94,312 shares of the biopharmaceutical company’s stock valued at $2,508,000 after buying an additional 5,632 shares in the last quarter. Finally, Blue Trust Inc. grew its stake in shares of Pfizer by 14.9% during the 4th quarter. Blue Trust Inc. now owns 61,517 shares of the biopharmaceutical company’s stock valued at $1,780,000 after acquiring an additional 7,958 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Pfizer

In other news, Director Scott Gottlieb purchased 1,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. This trade represents a 11.11 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have weighed in on PFE shares. Citigroup initiated coverage on shares of Pfizer in a report on Friday, October 25th. They set a “neutral” rating and a $30.00 price target on the stock. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a report on Tuesday, December 10th. Guggenheim lowered their price objective on Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Finally, Wolfe Research started coverage on Pfizer in a research note on Friday, November 15th. They set an “underperform” rating and a $25.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have issued a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer has an average rating of “Moderate Buy” and an average target price of $32.00.

Pfizer Stock Performance

Shares of NYSE:PFE opened at $26.10 on Monday. The firm has a fifty day simple moving average of $26.11 and a two-hundred day simple moving average of $27.94. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63. The stock has a market capitalization of $147.89 billion, a P/E ratio of 35.27, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, topping the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm’s revenue for the quarter was up 31.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.17) earnings per share. On average, analysts expect that Pfizer Inc. will post 2.94 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.59%. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. Pfizer’s payout ratio is presently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.